Have a feature idea you'd love to see implemented?
Let us know!
MCRB Seres Therapeutics Inc
Price (delayed)
$0.9509
Market cap
$162.35M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.23
Enterprise value
$179.27M
Seres Therapeutics, Inc., is a leading microbiome therapeutics platform company developing a novel class of multifunctional bacterial consortia that are designed to functionally interact with host cells and tissues to
Highlights
The equity has soared by 127% QoQ
Seres Therapeutics's net income has soared by 84% from the previous quarter and by 82% YoY
The quick ratio has shrunk by 52% YoY but it rose by 28% QoQ
MCRB's revenue has dropped by 100% year-on-year
Seres Therapeutics's gross profit has shrunk by 100% YoY
Key stats
What are the main financial stats of MCRB
Market
Valuations
Earnings
Shares outstanding
170.74M
Market cap
$162.35M
Enterprise value
$179.27M
Price to earnings (P/E)
N/A
Price to book (P/B)
6.03
Price to sales (P/S)
2,268.02
EV/EBIT
N/A
EV/EBITDA
77.17
EV/Sales
2,801.09
Revenue
$64,000
Gross profit
$64,000
Net income
-$25.48M
EBIT
-$13.34M
EBITDA
$2.32M
Free cash flow
-$158.39M
Per share
Balance sheet
Liquidity
EPS
-$0.23
EPS diluted
-$0.23
Free cash flow per share
-$1.04
Book value per share
$0.16
Revenue per share
$0
TBVPS
$1.17
Total assets
$178.74M
Total liabilities
$154.82M
Debt
$93.61M
Equity
$23.92M
Working capital
$8.1M
Debt to equity
3.91
Current ratio
1.12
Quick ratio
1.18
Net debt/EBITDA
7.28
Margins
Efficiency
Dividend
EBITDA margin
3,629.7%
Gross margin
100%
Net margin
-39,804.7%
Operating margin
-218,167.2%
Return on assets
-8.5%
Return on equity
N/A
Return on invested capital
-4.7%
Return on capital employed
-11.7%
Return on sales
-20,837.5%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
MCRB stock price
How has the Seres Therapeutics stock price performed over time
Intraday
-0.95%
1 week
3.26%
1 month
8.43%
1 year
-29.04%
YTD
-32.08%
QTD
0.51%
Financial performance
How have Seres Therapeutics's revenue and profit performed over time
Revenue
$64,000
Gross profit
$64,000
Operating income
-$139.63M
Net income
-$25.48M
Gross margin
100%
Net margin
-39,804.7%
MCRB's revenue has dropped by 100% year-on-year
Seres Therapeutics's gross profit has shrunk by 100% YoY
MCRB's net margin has surged by 84% since the previous quarter
Seres Therapeutics's net income has soared by 84% from the previous quarter and by 82% YoY
Growth
What is Seres Therapeutics's growth rate over time
Valuation
What is Seres Therapeutics stock price valuation
P/E
N/A
P/B
6.03
P/S
2,268.02
EV/EBIT
N/A
EV/EBITDA
77.17
EV/Sales
2,801.09
The EPS has soared by 81% QoQ and by 79% YoY
The equity has soared by 127% QoQ
The stock's price to sales (P/S) is 131% more than its last 4 quarters average of 993.2
MCRB's revenue has dropped by 100% year-on-year
Efficiency
How efficient is Seres Therapeutics business performance
The ROS has soared by 91% QoQ
The return on invested capital has surged by 90% year-on-year and by 90% since the previous quarter
The company's return on assets has surged by 82% QoQ and by 79% YoY
Dividends
What is MCRB's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for MCRB.
Financial health
How did Seres Therapeutics financials performed over time
The total assets is 15% higher than the total liabilities
The total liabilities has plunged by 62% from the previous quarter and by 60% YoY
MCRB's current ratio has shrunk by 59% YoY and by 19% QoQ
Seres Therapeutics's debt to equity has surged by 128% YoY
The equity has soared by 127% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.